All Oncology News

Premier Awards Program Recently Named 2014 Giants Class; Event to Honors New York Area Physicians

Health care professionals, including primary care physicians, cardiologists, oncologists, and psychiatrists are using their mobile devices (ie, smartphones and tablets) less, as compared to last year, and find themselves spending more time on a daily basis in front of their desktop computers

Patients who receive genetic counseling before they undergo testing are educated about these tests and may have fewer unnecessary procedures

The FDA has approved the radioactive diagnostic imaging agent Lymphoseek (technetium 99m tilmanocept) Injection to guide sentinel lymph node biopsy in patients with cancer of the head and neck.

The FDA has approved gadobutrol (Gadavist) injection for intravenous use with breast MRI to detect and identify the extent of disease

The phase III REACH trial, which examined ramucirumab (Cyramza) for the second-line treatment of patients with hepatocellular carcinoma (HCC), failed to meet its primary endpoint of overall survival (OS), as announced by Eli Lilly and Company, the sponsor of the study and developer of the drug.

Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Bundled payments are no longer being relegated to pilot program status, according to a report from the Health Care Incentives Improvement Institute (HCI3). Instead, more and more public and private payers are committing to this model as a core payment and delivery reform strategy.

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

A retrospective analysis of pharmacy and medical claims conducted by WellPoint shows that the costs to treat and care for cancer patients can be 3% to 14% less, depending on cancer type, when it is provided by oncologist-owned practices versus hospital-owned practices.

A new independently validated lab test is now available that takes advantage of the extensive database of gene mutations amassed by Memorial Sloan Kettering (MSK) Cancer Center.

Premier Awards Program Presented by OncLive Names 2014 Cancer Care Luminaries

Two of North America's leading cancer centers announced what is likely the largest collaboration of its kind to accelerate discoveries in cancer research.

Although the deadline for ICD-10 implementation has been moved to October 1, 2015, the Centers for Medicare & Medicaid Services (CMS) has developed, in collaboration with physicians, a free tool that is specialty-specific and offers customizable, actionable advice and tips to ease physician practices through the transition to ICD-10.

Study raises concern about surgical "margins" for acral melanoma tumors, known to target the darker skins of Asians, African-Americans and Hispanics

Maurie Markman, MD, the editor-in-chief of OncologyLive magazine, has been named president of the Medicine & Science unit at Cancer Treatment Centers of America.

Only a Few of More Than 109 Detected Strains Known to Cause Cancer

A new reimbursement program initiated by WellPoint, Inc., looks to pay oncologists an additional $350 a month for each patient who is enrolled in and follows one of the insurer's recommended cancer treatment regimens

The ASCO clinical practice guideline now recommends treatment with adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor-positive breast cancer.

Nearly 72% of office-based physician practices were using electronic health records (EHRs) in 2012, marking the slow and eventual decline of paper medical charts, according to a new report from the National Center for Health Statistics. From 2007 through 2012, use of any type of EHR system increased across all physician and practice categories, with the exception of HMO-owned practices.

$12 million in grants pursued by TGen-George Mason Molecular Medicine Alliance, leveraging institutes' expertise in genomics and proteomics.

Cutting-edge translational research pioneer will work with OncLive to promote knowledge of genetic research and its application to patient care.

The FDA has expanded the approval of panitumumab to include the frontline treatment of patients with KRAS wild-type mCRC in combination with chemotherapy.

Part of the Medical Center's Commitment to a "Supportive Oncology" Approach to Cancer Treatment

Physician practices that provide care to patients who have enrolled in the Affordable Care Act's (ACA) health exchanges are finding it difficult to complete some basic administrative tasks.

For patients whose colorectal cancer has spread to the liver, and confirmed by computed tomography (CT), further imaging scans before surgery added little benefit when compared to patients who did not undergo further imaging.

CO-1686 has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic T790M mutation-positive NSCLC who have received at least one prior line of EGFR-targeted therapy.

A phase III study exploring the chemotherapy regimen DHAP plus ofatumumab failed to meet its primary endpoint of prolongation in PFS when compared with DHAP plus rituximab for patients with relapsed or refractory DLBCL.

Over the course of only a few days, two drugs that will be commercialized by Bristol-Myers Squibb (BMS), nivolumab and elotuzumab, have each been granted breakthrough therapy designations by the FDA for the treatment of two different types of blood cancers.

WETA, the Washington, DC, public television station, has launched a new website as part of a national outreach for the documentary The Story of Cancer: The Emperor of All Maladies, which will be produced by Ken Burns.